EGFR Mutation Status in Primary Lung Adenocarcinomas and Corresponding Metastatic Lesions: Discordance in Pleural Metastases

Han, Hye‐Suk; Eom, Dae-Woon; Kim, Joo Heon; Kim, Kyung‐Hee; Shin, Hyang-Mi; An, Jin; Lee, Ki Man; Choe, Kang Hyeon; Lee, Ki Hyeong; Kim, Seung Taik; Koo, Ji Hae; Lee, Ho-chang; Lee, Ok-Jun

doi:10.1016/j.cllc.2011.02.006

Cited by 109 publications

(87 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This phenomenon has been reported previously (35) and raises the possibility that EGFR mutation is positively correlated with tumor progression. We also observed different patterns of metastatic locations between patients with EGFR mutation-positive and mutation-negative NSCLC.…”

Section: Discussionsupporting

confidence: 84%

EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study

Schuette

Stella

Eberhardt

et al. 2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Introduction: EGFR mutations confer sensitivity to EGFR tyrosine kinase inhibitors (TKI) in advanced non-small cell lung cancer (NSCLC). We investigated the clinicopathologic characteristics associated with EGFR mutations and their impact on realworld treatment decisions and outcomes in Caucasian patients with advanced NSCLC.Methods: REASON (NCT00997230) was a noninterventional multicenter study in patients (!18 years) with stage IIIb/IV NSCLC, who were candidates for EGFR mutation testing and first-line systemic treatment, but not eligible for surgery or radiotherapy. Patients were followed up according to normal clinical practice and assessed for primary (correlation of mutation status with baseline characteristics) and secondary endpoints (first-line treatment decision).Results: Baseline data were obtained for 4,200 patients; 4,196 fulfilled the inclusion criteria; EGFR mutations were detected in 431 patients; no EGFR mutations were detected in 3,590 patients;

show abstract

Section: Discussionsupporting

confidence: 84%

EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study

Schuette

Stella

Eberhardt

et al. 2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…28 Conversely, the heterogeneity of EGFR mutation status in lung cancer suggests that tumours include cancer cells with both mutated and wild-type alleles. A study in Korea comparing EGFR status between paired primary tumour and MPE tissues showed a significant discordance (more mutations in MPE), 26 suggesting that EGFR mutations facilitate the migration of cancer cells into the pleural cavity. The frequency of EGFR mutation in patients with stage IV disease in the present study was significantly higher in those with MPE than in those without, further implicating EGFR mutation in the development of MPE.…”

Section: Discussionmentioning

confidence: 99%

Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation

et al. 2014

View full text Add to dashboard Cite

Objective: A retrospective single-centre study to compare the clinical features of patients with lung adenocarcinoma with and without epidermal growth factor receptor (EGFR) mutations. Methods: Pretreatment medical records of patients with lung adenocarcinoma were reviewed. DNA was extracted from paraffin wax-embedded tumour tissue for analysis of EGFR mutations. Malignant pleural effusion (MPE) was diagnosed by cytopathological testing of pleural fluid. Results: EGFR mutations (19-Del and L858R) were recorded in 81/283 patients (28.6%). MPE was found in 42/283 patients (14.8%). In patients with stage IV disease, the frequency of EGFR mutations was higher in those with MPE than in those without MPE. EGFR mutations were independently associated with female sex, no history of smoking and presence of MPE. Conclusions: There was a positive association between EGFR mutation and the presence of MPE. EGFR mutations may play an important role in the formation of MPE.

show abstract

“…According to several studies, the discordance rate of EGFR mutations ranged between 16.2% to 32.5%. [59][60][61][62] Emerging clinical data in studies testing a molecularly matched targeted therapy approach particularly in mutation-enriching patient populations using clinicopathological parameters, for example, the IPASS, have now strengthened the notion that molecular tumor selection by profiling trumps clinical selection. 63 The IPASS also paved the road for the arrival of the first-line use of EGFR TKI (erlotinib and gefitinib) in sensitizing EGFR mutation-positive advanced NSCLC patients.…”

Section: Egfr (Her1 or Erbb1)mentioning

confidence: 99%

“…For instance, the use of laser microdissection or whole genome amplification and the specific sequencing method should be reported. Moreover, it would be crucially important to specify in studies whether the sequencing was performed from primary versus metastatic tumor sites [59][60][61][62] and, if the latter, which specific organ site of metastasis.…”

Section: Lung Cancer Genome Analysis: Ngs and Future Directionsmentioning

confidence: 99%

Cancer Genes in Lung Cancer: Racial Disparities: Are There Any?

2012

View full text Add to dashboard Cite

Cancer is now known as a disease of genomic alterations. Mutational analysis and genomics profiling in recent years have advanced the field of lung cancer genetics/genomics significantly. It is becoming more accepted now that the identification of genomic alterations in lung cancer can impact therapeutics, especially when the alterations represent "oncogenic drivers" in the processes of tumorigenesis and progression. In this review, we will highlight the key driver oncogenic gene mutations and fusions identified in lung cancer. The review will summarize and report the available demographic and clinicopathological data as well as molecular details behind various lung cancer gene alterations in the context of race. We hope to shed some light into the disparities in the incidence of various genetic mutations among lung cancer patients of different racial backgrounds. As molecularly targeted therapy continues to advance in lung cancer, racial differences in specific genetic/genomic alterations can have an important impact in the choices of therapeutics and in our understanding of the drug sensitivity/resistance profile. The most relevant genes in lung cancer described in this review include the following: EGFR, KRAS, MET, LKB1, BRAF, PIK3CA, ALK, RET, and ROS1. Commonly identified genetic/genomic alterations such as missense or nonsense mutations, small insertions or deletions, alternative splicing, and chromosomal fusion rearrangements were discussed. Relevance in current targeted therapeutic drugs was mentioned when appropriate. We also highlighted various targeted therapeutics that are currently under clinical development, such as the MET inhibitors and antibodies. With the advent of next-generation sequencing, the landscape of genomic alterations in lung cancer is expected to be much transformed and detailed in upcoming years. These genomic landscape differences in the context of racial disparities should be emphasized both in tumorigenesis and in drug sensitivity/resistance. It is hoped that such effort will help to diminish racial disparities in lung cancer outcome in the future.

show abstract

EGFR Mutation Status in Primary Lung Adenocarcinomas and Corresponding Metastatic Lesions: Discordance in Pleural Metastases

Cited by 109 publications

References 34 publications

EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study

EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study

Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation

Cancer Genes in Lung Cancer: Racial Disparities: Are There Any?

Contact Info

Product

Resources

About